JP2022521048A - 食品サプリメント - Google Patents
食品サプリメント Download PDFInfo
- Publication number
- JP2022521048A JP2022521048A JP2021545685A JP2021545685A JP2022521048A JP 2022521048 A JP2022521048 A JP 2022521048A JP 2021545685 A JP2021545685 A JP 2021545685A JP 2021545685 A JP2021545685 A JP 2021545685A JP 2022521048 A JP2022521048 A JP 2022521048A
- Authority
- JP
- Japan
- Prior art keywords
- galactose
- group
- supplement
- composition
- supplements
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 74
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 23
- 229930182558 Sterol Natural products 0.000 claims abstract description 20
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 20
- 150000003432 sterols Chemical class 0.000 claims abstract description 20
- 235000003702 sterols Nutrition 0.000 claims abstract description 20
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 19
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 16
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 239000000284 extract Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 24
- 235000008210 xanthophylls Nutrition 0.000 claims description 18
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 16
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 16
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 16
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 16
- 150000003735 xanthophylls Chemical class 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 230000006400 anxiety behaviour Effects 0.000 claims description 10
- 239000002540 palm oil Substances 0.000 claims description 9
- 230000003920 cognitive function Effects 0.000 claims description 8
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 8
- 241000206759 Haptophyceae Species 0.000 claims description 6
- 235000019482 Palm oil Nutrition 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 5
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims description 5
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- 150000002535 isoprostanes Chemical class 0.000 claims description 4
- 241001467606 Bacillariophyceae Species 0.000 claims description 3
- 241000206751 Chrysophyceae Species 0.000 claims description 3
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 3
- 241001037764 Isochrysidaceae Species 0.000 claims description 3
- 208000030979 Language Development disease Diseases 0.000 claims description 3
- 241000983121 Mamiellophyceae Species 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 241000206744 Phaeodactylum tricornutum Species 0.000 claims description 3
- 241000031610 Pinguiophyceae Species 0.000 claims description 3
- 241001364248 Tisochrysis lutea Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000008393 encapsulating agent Substances 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 256
- 239000013589 supplement Substances 0.000 description 158
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 106
- 230000000694 effects Effects 0.000 description 92
- 239000000546 pharmaceutical excipient Substances 0.000 description 88
- 238000012360 testing method Methods 0.000 description 54
- 229940090949 docosahexaenoic acid Drugs 0.000 description 53
- 231100000739 chronic poisoning Toxicity 0.000 description 42
- 238000011282 treatment Methods 0.000 description 41
- 230000035882 stress Effects 0.000 description 40
- 208000035475 disorder Diseases 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 32
- 239000011780 sodium chloride Substances 0.000 description 31
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 27
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 27
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 27
- 241000700159 Rattus Species 0.000 description 26
- 102000004889 Interleukin-6 Human genes 0.000 description 25
- 108090001005 Interleukin-6 Proteins 0.000 description 25
- 239000003240 coconut oil Substances 0.000 description 23
- 235000019864 coconut oil Nutrition 0.000 description 23
- 229940100601 interleukin-6 Drugs 0.000 description 23
- 239000013642 negative control Substances 0.000 description 22
- 238000011321 prophylaxis Methods 0.000 description 21
- 230000003859 lipid peroxidation Effects 0.000 description 20
- 230000002238 attenuated effect Effects 0.000 description 17
- 230000015654 memory Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 230000036542 oxidative stress Effects 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 14
- 230000001149 cognitive effect Effects 0.000 description 14
- 230000035987 intoxication Effects 0.000 description 13
- 231100000566 intoxication Toxicity 0.000 description 13
- 208000028698 Cognitive impairment Diseases 0.000 description 12
- 238000001061 Dunnett's test Methods 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 12
- 238000012347 Morris Water Maze Methods 0.000 description 11
- 201000003723 learning disability Diseases 0.000 description 11
- 230000007774 longterm Effects 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000007596 spatial working memory Effects 0.000 description 10
- 230000003542 behavioural effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 9
- 239000002028 Biomass Substances 0.000 description 8
- 238000009227 behaviour therapy Methods 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 230000003959 neuroinflammation Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000006886 spatial memory Effects 0.000 description 8
- 230000007000 age related cognitive decline Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000008092 positive effect Effects 0.000 description 7
- 238000007493 shaping process Methods 0.000 description 7
- 230000031836 visual learning Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 6
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 229960005375 lutein Drugs 0.000 description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- -1 troches Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000002457 bidirectional effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000006999 cognitive decline Effects 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229940068065 phytosterols Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000282341 Mustela putorius furo Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000737241 Cocos Species 0.000 description 2
- OGHZCSINIMWCSB-GHIQLMQGSA-N Diadinoxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C#CC1=C(C)C[C@@H](O)CC1(C)C OGHZCSINIMWCSB-GHIQLMQGSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010021033 Hypomenorrhoea Diseases 0.000 description 2
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 2
- 208000020358 Learning disease Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241001520859 Phaeodactylaceae Species 0.000 description 2
- 241000206731 Phaeodactylum Species 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229930186770 diadinoxanthin Natural products 0.000 description 2
- OGHZCSINIMWCSB-WEWHBREISA-N diadinoxanthin A Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C#CC1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC23OC2(C)CC(O)CC3(C)C OGHZCSINIMWCSB-WEWHBREISA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000021824 exploration behavior Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- OSELKOCHBMDKEJ-WGMIZEQOSA-N isofucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC/C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-WGMIZEQOSA-N 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000002314 neuroinflammatory effect Effects 0.000 description 2
- 238000012316 non-parametric ANOVA Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 238000011302 passive avoidance test Methods 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical class OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- NBZANZVJRKXVBH-DJPRRHJBSA-N (3R,6'R)-beta,epsilon-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=CCCC1(C)C NBZANZVJRKXVBH-DJPRRHJBSA-N 0.000 description 1
- PXGPLTODNUVGFL-PGWUFSIFSA-N 15-epi-15-F2t-IsoP Chemical compound CCCCC[C@@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-PGWUFSIFSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- INDVLXYUCBVVKW-RNWIMVDMSA-N 24-Methylene cholesterol Natural products O[C@@H]1CC=2[C@@](C)([C@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCC(C(C)C)=C)C)CC4)CC3)CC=2)CC1 INDVLXYUCBVVKW-RNWIMVDMSA-N 0.000 description 1
- INDVLXYUCBVVKW-PXBBAZSNSA-N 24-methylenecholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(=C)C(C)C)[C@@]1(C)CC2 INDVLXYUCBVVKW-PXBBAZSNSA-N 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 1
- GKBLNJXQDMHILB-DDGADJJWSA-N 9-epi-9-F1t-PhytoP Chemical compound CC[C@H]1[C@H](O)C[C@H](O)[C@H]1\C=C\[C@H](O)CCCCCCCC(O)=O GKBLNJXQDMHILB-DDGADJJWSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- IFYMEZNJCAQUME-APKWKYNESA-N Chrysanthemaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3=C(C)CC(O)CC3(C)C IFYMEZNJCAQUME-APKWKYNESA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- HNYJHQMUSVNWPV-DRCJTWAYSA-N Diatoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1C#CC(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C HNYJHQMUSVNWPV-DRCJTWAYSA-N 0.000 description 1
- HNYJHQMUSVNWPV-QWJHPLASSA-N Diatoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C#CC1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C HNYJHQMUSVNWPV-QWJHPLASSA-N 0.000 description 1
- PVNVIBOWBAPFOE-UHFFFAOYSA-N Dinoxanthin Natural products CC1(O)CC(OC(=O)C)CC(C)(C)C1=C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1(C(CC(O)C2)(C)C)C2(C)O1 PVNVIBOWBAPFOE-UHFFFAOYSA-N 0.000 description 1
- 239000004211 Flavoxanthin Substances 0.000 description 1
- JRHJXXLCNATYLS-NGZWBNMCSA-N Flavoxanthin Chemical compound C/C([C@H]1C=C2C(C)(C)C[C@H](O)C[C@@]2(C)O1)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C JRHJXXLCNATYLS-NGZWBNMCSA-N 0.000 description 1
- QHUMOJKEVAPSCY-JOJDNVQPSA-N Flavoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1(C)OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CC(O)CC3(C)C)C QHUMOJKEVAPSCY-JOJDNVQPSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 241001245608 Isochrysidales Species 0.000 description 1
- INDVLXYUCBVVKW-UHFFFAOYSA-N Methylencholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=C)C(C)C)C1(C)CC2 INDVLXYUCBVVKW-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- PGYAYSRVSAJXTE-CLONMANBSA-N all-trans-neoxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O PGYAYSRVSAJXTE-CLONMANBSA-N 0.000 description 1
- NBZANZVJRKXVBH-GYDPHNCVSA-N alpha-Cryptoxanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@H]2C(C)=CCCC2(C)C)\C)/C)\C)/C)=C(C)C1 NBZANZVJRKXVBH-GYDPHNCVSA-N 0.000 description 1
- 235000005861 alpha-cryptoxanthin Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001651 autotrophic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical group C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- RQXBHXSBLSHCPO-KYFQLVDCSA-N ent-16-epi-16-F1t-PhytoP Chemical compound CC[C@H](O)\C=C\[C@@H]1[C@@H](O)C[C@@H](O)[C@@H]1CCCCCCCC(O)=O RQXBHXSBLSHCPO-KYFQLVDCSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019243 flavoxanthin Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- OWAAYLVMANNJOG-OAKWGMHJSA-N neoxanthin Natural products CC(=C/C=C(C)/C=C/C=C(C)/C=C=C1C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC23OC2(C)CC(O)CC3(C)C OWAAYLVMANNJOG-OAKWGMHJSA-N 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000956 solid--liquid extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
微細藻類は、理想的には、レースウェイ、オープンポンドのような適合されたシステム内で、又は、好ましくはフォトバイオリアクターのようなクローズドシステム内で、制御された様式で培養される。使用されるフォトバイオリアクターは既存の形式であって良い。例えば、水平管状フォトバイオリアクター、垂直型の、いわゆる「グリーンウォールパネル」システム、平面型又はカラム型のフォトバイオリアクター等であっても良い。望ましくは、バイオマスの生産は、耕地に対してゼロインパクトの独立栄養により、密閉栽培システム内にて行われる。
これらの微生物に由来する抽出物は、バイオマスから水の全て又は一部を除去する遠心分離、ろ過、凝集、沈降等の化学的又は物理的プロセスを用いた濃縮の後に、組み合わせるかどうかは無関係に、凍結乾燥、真空乾燥、ドラム乾燥、噴霧又は他のバイオマス中の水分量を下げられる任意の工程による乾燥工程において得るのが好ましい。
抽出物の製剤は、望ましい濃度を有する均一な溶液を得るために、抽出物を溶解可能な互換性のある基剤を用いて行われ、例えば、オリーブ油、コルザ油、アマニ油、ヒマワリ油、ブドウ種子油、パーム油、及び好ましくはMCT油のような植物油等を用いる。カプリル酸及びカプリン酸、望ましくはココナッツ油又はパーム油から選択される70重量%の混合物として構成され、且つ全体が合成又は天然の抗酸化剤のような安定性を向上可能な分子により補充される。サプリメントを得るための基剤/添加物の配合重量は、食品サプリメントの重量に対して95重量%に達することができる。一般には、15~80%の間であり、望ましくは35~45%の間である。
抽出物は、フェオダクチラム・トリコナータム(Phaeodactylum tricornutum)から、上記に説明したいずれかの技術によって得られる。
本発明の食品サプリメントは、チソクリシス・ルテア抽出物から調製され、これは、mg/gの単位で以下を含有する:
オメガ-3型脂肪酸(ALA,SDA,EPA,DHA):152.6 ± 14.4;
フコキサンチン:20.0 ± 4.0;
ステロール:4.9 ± 0.8;
フィコプロスタン:0.035 ± 0.007。
・14日目と51日目との間、サプリメントは食品ペレットに配合することで投与される;
・1日目と51日目との間、D-ガラクトースは週に5日、皮下投与される;
・43日目と51日目との間に、3つの異なる行動テストを用いて、試験化合物の効果をモニターする。
・43日目、全ての動物について、空間作業記憶指数を介し、Y字迷路(YM)試験において自発的交替性能の試験を行った。
・44日目から49日目において、全ての動物について、空間記憶指数を介し、モリス水迷路(MWM:Morris Water Maze)試験において空間記憶の試験を行った。
・50日目及び51日目において、動物の長期文脈記憶を評価した。これには、運動及び保持セッションを通し、段階型受動回避プロセス(DTPA:step-by-step type passive avoidance process)を用いた。
・50日目及び51日目において、全ての動物について、STPA課題について試験した。
51日目に、行動試験の後、動物を安楽死させた。
HPCE = A5801 / A5802 × [HPC (nmol)]
そして組織湿重量あたりHPC当量において、対象群(D-ガラクトース + 賦形剤)について得られたデータに対して百分率で表される。
IL-6の定量:ThermoScientifique社のEM2IL6
TNF-αの定量:ThermoScientifique社のEMTNFA
全ての試験について、50mMのトリス緩衝生理食塩水(Tris-150 mM NaCl)、pH 7.5内にて解凍した後、皮質を均質化(homogenize)し、20秒間超音波処理する。遠心分離(16100 g、15分間、4℃)の後、上澄み又は血漿を、ELISA試験の製造業者の指示に従って、ELISA試験に用いる。試験毎に、吸光度を450 nmにおいて読み取り、標準曲線を用いて、サンプルの濃度を計算する。結果は、mg単位の組織湿重量あたりのマーカーのpgにより表される。
グループ1は、D-ガラクトースに代えて生理食塩水が皮下投与され且つ偽ブルA1が与えられるグループである;
グループ2は、D-ガラクトース及びキブルA1が投与されるグループである;
グループ3は、D-ガラクトース及びキブルA2が投与されるグループである;
グループ4は、D-ガラクトース及びキブルA3が投与されるグループである;
グループ5は、D-ガラクトース及びキブルA4が投与されるグループである;
グループ6は、D-ガラクトース及びキブルA5が投与されるグループである。
結果を図1に示し、第1の図(左側)は、自発的交替障害に対する本発明のサプリメントの効果を示し、第2の図(右側)は、自発運動活性に対する本発明のサプリメントの効果を示す。
結果を図2に示す。
結果を図3に示す。
結果は図4に示されている。本発明のサプリメントの効果は、保持期間中に測定された、左側の図のステップダウン潜時及び右側の図の回避潜時にそれぞれ示される。
結果を図5に示す。
結果を図6に示す。皮質への効果を左側の図に、血漿への効果を右側の図に示す。
結果を図7に示す。皮質への効果を左側の図に、血漿への効果を右側の図に示す。
D-ガラクトースによる慢性中毒は、空間作業記憶、長期文脈記憶に極めて顕著に変化を誘発し、空間学習に害を与える。行動の変化は、酸化ストレスの増加、神経炎症プロセスの誘発等の生化学的な変化とも関連している。
本実施例では、祖先の出生前ストレス後の若い雌ラットにおける認知障害、不安行動及び認識記憶の変化の解消を検討する。これは、実施例2において用いた微細藻類チソクリシス・ルテア抽出物に基づくサプリメントの投与を通して行う。
この実施例にて用いるモデルは、厳しい照明下で円筒内に妊娠した雌を固定することによりラットに出生前ストレスを誘発する、認知されたモデルである。
グループ1は、12匹のナイーブ雌ラット、つまり、祖先が出生前ストレスに曝されていないラットから構成され、且つ、1日に200μLの賦形剤溶液のみを受ける(NS/賦形剤と呼ぶ)。従って、このグループは対照グループである。
結果を図8に示す。
出生前ストレスに曝され且つサプリメントにより予防的治療を受けたグループSP/サプリメントは、グループSP/賦形剤(出生前ストレスに曝されたがサプリメントによる治療を受けていないグループ)と比較して、オープン試験空間の周辺において顕著に低い移動のパーセンテージを有する。更に、グループSP/サプリメントにおける移動のパーセンテージ分布は、コントロールのグループNS/賦形剤と同等である。
結果は図9に示されている。
テストの結果は図10に示されている。
サプリメントによる治療は、顕著に且つ完全に不安行動を減弱し、出生前ストレスにより誘発された認知記憶障害を減弱する。
本発明の食品サプリメントは、フェオダクチラム・トリコナータム抽出物から調製され、mg/gにおいて以下を含む:
オメガ-3型脂肪酸(ALA,SDA,EPA,DHA):66.6 ± 11.5;
フコキサンチン:20.0 ± 4.0;
ステロール:3.0 ± 0.6;
フィコプロスタン:0.0025 ± 0.0005。
・28日目から51日目の間、食物ペレットに組み込むことで投与される;
・01日目から51日目の間、D-ガラクトースを週に5日、皮下投与する;
・43日目から51日目の間、3つの異なる行動試験を用いて、試験組成物の効果をモニターする。
・43日目に、全ての動物について、空間作業記憶インデックスを介して、Y字迷路(YM)試験における自発的交替性能を試験した;
・44日目から49日目まで、全ての動物について、空間記憶インデックスを介して、モリス水迷路(MWM)試験における空間記憶を試験した;
・44日目から49日目まで、全ての動物について、空間作業記憶を評価するためにMWM試験により試験した;
・50日目及び51日目に、運動及び保持セッションを通じて、段階型受動回避プロセス(STPA)を使用して、動物の長期文脈記憶を試験した。
51日目に、行動試験の後、動物を安楽死させた。
HPCE = A5801 / A5802 × [HPC (nmol)]
そして組織湿重量あたりHPC当量において、対象群(D-ガラクトース + 賦形剤)について得られたデータに対して百分率で表される。
IL-6の定量:ThermoScientifique社のEM2IL6
TNF-αの定量:ThermoScientifique社のEMTNFA
全ての試験について、50mMのトリス緩衝生理食塩水(Tris-150 mM NaCl)、pH 7.5内にて解凍した後、皮質を均質化(homogenize)し、20秒間超音波処理する。遠心分離(16100 g、15分間、4℃)の後、上澄み又は血漿を、ELISA試験の製造業者の指示に従って、ELISA試験に用いる。試験毎に、吸光度を450nmにおいて読み取り、標準曲線を用いて、サンプルの濃度を計算する。結果は、mg単位の組織湿重量あたりのマーカーのpgにより表される。
結果を図11に示し、第1の図(左側)は、自発的交替障害に対する本発明のサプリメントの効果を示し、第2の図(右側)は、自発運動活性に対する本発明のサプリメントの効果を示す。
結果を図12に示す。
結果を図13に示す。
結果は図14に示されている。本発明のサプリメントの効果は、保持期間中に測定された、左側の図のステップダウン潜時及び右側の図の回避潜時にそれぞれ示される。
結果は図15に示されている。
結果を図16に示す。皮質への効果を左側の図に、血漿への効果を右側の図に示す。
結果を図17に示す。皮質への効果を左側の図に、血漿への効果を右側の図に示す。
D-ガラクトースによる慢性中毒は、空間作業記憶及び長期文脈記憶の変化を顕著に誘発し、空間学習を害した。行動の変化は、酸化ストレスの増加及び神経炎症プロセス活性化に現れる生化学的変化にも関連している。
Claims (18)
- 少なくとも50 mg/gの1つ又は複数のオメガ-3型脂肪酸と、
少なくとも10 mg/gの1つ又は複数のキサントフィルと、
少なくとも1 mg/gの1つ又は複数のステロールと、
少なくとも2μg/gの1つ又は複数のフィコプロスタンとを含む組成物。 - 請求項1の組成物において、
50~250 mg/gの1つ又は複数のオメガ-3型脂肪酸と、
10~50 mg/gの1つ又は複数のキサントフィルと、
1~20 mg/gの1つ又は複数のステロールと、
2~100 μg/gの1つ又は複数のフィコプロスタンとを含むことを特徴とする組成物。 - 請求項1又は2の組成物において、
50~200 mg/gの1つ又は複数のオメガ-3型脂肪酸と、
10~30 mg/gの1つ又は複数のキサントフィルと、
1~8 mg/gの1つ又は複数のステロールと、
2~50 μg/gの1つ又は複数のフィコプロスタンとを含むことを特徴とする組成物。 - 請求項1~3のいずれか1つの組成物において、
50~170 mg/gの1つ又は複数のオメガ-3型脂肪酸と、
10~25 mg/gの1つ又は複数のキサントフィルと、
1~6 mg/gの1つ又は複数のステロールと、
2~40 μg/gの1つ又は複数のフィコプロスタンとを含むことを特徴とする組成物。 - 請求項1~4のいずれか1つの組成物と、
中鎖トリグリセリド(MCT)から選ばれる少なくとも1つの油脂とを含む食品サプリメント。 - 請求項5の食品サプリメントにおいて、
前記中鎖トリグリセリド(MCT)は、ココナッツパーム油及びパーム油から選ばれることを特徴とする食品サプリメント。 - 前記オメガ-3型脂肪酸の少なくとも1つは、ステアドリン酸(SDA)、エイコサペンタエン酸(EPA)、ドコサヘキサエン酸(DHA)及びこれらの混合物から選ばれることを特徴とする、請求項1~4のいずれか1つの組成物又は請求項5若しくは6の食品サプリメント。
- 前記キサントフィルの少なくとも1つが、フコキサンチンであることを特徴とする、請求項1~4及び7のいずれか1つの組成物又は請求項5~7のいずれか1つの食品サプリメント。
- 前記ステロールの少なくとも1つが、フィトステロールであることを特徴とする、請求項1~4及び7~8のいずれか1つの組成物又は請求項5~8のいずれか1つの食品サプリメント。
- 前記フィコプロスタンの少なくとも1つが、フィトプロスタン、イソプロスタン及びニューロプラスタンから選ばれることを特徴とする、請求項1~4及び7~9のいずれか1つの組成物又は請求項5~9のいずれか1つの食品サプリメント。
- 防腐剤、着色剤、香料、崩壊剤、潤滑剤、コーティング剤又はカプセル化剤から選ばれる少なくとも1つの添加物を更に含むことを特徴とする、請求項1~4及び7~10のいずれか1つの組成物又は請求項5~10のいずれか1つの食品サプリメント。
- ゲルカプセル、カプセル、錠剤、トローチ又は荒い粉末の形を取っていることを特徴とする、請求項1~4及び7~11のいずれか1つの組成物又は請求項5~11のいずれか1つの食品サプリメント。
- 10mgから1gの間の単位重量を有する服用量にパッケージされていることを特徴とする、請求項1~4及び7~12のいずれか1つの組成物又は請求項5~12のいずれか1つの食品サプリメント。
- 請求項1~4及び7~13のいずれか1つの組成物又は請求項5~13のいずれか1つの食品サプリメントを調製するための、ピングイオ藻綱(Pinguiophyceae)、黄金色藻綱(Chrysophyceae)、珪藻綱(Bacillariophyceae)、マミエラ藻綱(Mamiellophyceae)、プリネシウム藻綱(Prymnesiophyceae)、ハプト藻綱(Haptophyceae)、コッコリサス藻綱(Coccolithophyceae)、イソクリシス目(Isochrysidaceae)及びフェオダクチラム属(Phaeodactylaceae)から選ばれる分類群(taxon)の微細藻類の使用方法。
- 請求項14において、
前記微細藻類は、チソクリシス・ルテア(Tisochrysis lutea)又はフェオダクチラム・トリコナータム(Phaeodactylum tricornutum)であることを特徴とする、微細藻類の使用方法。 - 非病理的な認知機能の減少として定義される加齢による認知機能障害、又は、多動、注意及び記憶障害、言語の遅延及び不安行動等の非病理的な障害を誘発する出生前ストレスに曝された小児又は若年成人の認知機能障害の発生を抑制するための、請求項5~13のいずれか1つの食品サプリメントの使用。
- 1日の服用量が、抽出物2~5 mg/体重1 kgの範囲であることを特徴とする、非病理的な認知機能の減少として定義される加齢による認知機能障害を抑制するための、請求項16の食品サプリメントの使用。
- 1日の服用量が、抽出0.05~0.1 mg/体重1 kgの範囲であることを特徴とする、多動、注意及び記憶障害、言語の遅延及び不安行動等の非病理的な障害を誘発する出生前ストレスに曝された小児又は若年成人の認知機能障害の発生を抑制するための、請求項16の食品サプリメントの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR19/01820 | 2019-02-22 | ||
FR1901820A FR3092968B1 (fr) | 2019-02-22 | 2019-02-22 | Complement alimentaire |
PCT/FR2020/050330 WO2020169936A1 (fr) | 2019-02-22 | 2020-02-21 | Complément alimentaire |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022521048A true JP2022521048A (ja) | 2022-04-05 |
Family
ID=67742539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021545685A Pending JP2022521048A (ja) | 2019-02-22 | 2020-02-21 | 食品サプリメント |
Country Status (13)
Country | Link |
---|---|
US (1) | US11806316B2 (ja) |
JP (1) | JP2022521048A (ja) |
KR (1) | KR20210130190A (ja) |
CN (1) | CN113924001A (ja) |
AU (1) | AU2020225432A1 (ja) |
BR (1) | BR112021016556A2 (ja) |
CA (1) | CA3142490A1 (ja) |
FR (1) | FR3092968B1 (ja) |
IL (1) | IL285726A (ja) |
MX (1) | MX2021009825A (ja) |
SG (1) | SG11202109081SA (ja) |
WO (1) | WO2020169936A1 (ja) |
ZA (1) | ZA202105588B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102467678B1 (ko) * | 2020-11-18 | 2022-11-17 | 한국과학기술연구원 | 티아이소크라이시스 루테아를 유효성분으로 포함하는 염증성 장질환 개선용 조성물 |
FR3130162A1 (fr) * | 2021-12-14 | 2023-06-16 | Microphyt | Composition et application notamment cosmétique |
WO2023242296A1 (fr) | 2022-06-16 | 2023-12-21 | Microphyt | Utilisation d'un extrait de microalgue seul ou en combinaison pour ameliorer les capacites cognitives |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002180082A (ja) * | 2000-12-11 | 2002-06-26 | Maruha Corp | 摂取物 |
SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
CN101098629B (zh) * | 2004-11-04 | 2010-10-13 | 孟山都技术公司 | 高pufa油组合物 |
KR20130101596A (ko) * | 2005-07-08 | 2013-09-13 | 마텍 바이오싸이언스스 코포레이션 | 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산 |
CA2688506A1 (en) * | 2007-05-31 | 2008-12-04 | Biocrates Life Sciences Ag | Inflammation and oxidative stress level assay |
WO2010088700A1 (en) * | 2009-02-02 | 2010-08-05 | Martek Biosciences Corporation | Methods for improving cognitive function and decreasing heart rate |
US20110177061A1 (en) * | 2009-07-10 | 2011-07-21 | Martek Biosciences Corporation | Methods of treating and preventing neurological disorders using docosahexaenoic acid |
US9763897B2 (en) * | 2010-04-30 | 2017-09-19 | U.S. Nutraceuticals, LLC | Therapeutic astaxanthin and phospholipid composition and associated method |
US20140205627A1 (en) * | 2010-04-30 | 2014-07-24 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin |
AU2011315835B2 (en) * | 2010-10-14 | 2016-02-04 | Asha Nutrition Sciences, Inc. | Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof |
WO2012156970A1 (en) | 2011-05-04 | 2012-11-22 | Magnetika Interactive Ltd. | Salvia sclarea seed oil for use in the treatment of cardiovascular diseases or anxiety disorders |
WO2013032333A1 (en) | 2011-09-01 | 2013-03-07 | Algae Biotech S.L. | Oral dosage units containing astaxanthin, phospholipids and omega-3 fatty acids |
KR20140052580A (ko) * | 2012-10-25 | 2014-05-07 | 조선대학교산학협력단 | 해조류에서 추출한 후코잔틴을 포함하는 신경보호용 조성물 |
WO2014155189A1 (en) * | 2013-03-28 | 2014-10-02 | Omniactive Health Technologies Ltd. | Neuroprotective effect of carotenoids in brain |
WO2015175478A1 (en) * | 2014-05-13 | 2015-11-19 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition using seed oil extracts and phospholipids to enhance absorption of carotenoids and associated methods |
MA40846A (fr) * | 2014-10-10 | 2017-09-05 | Sancilio & Company Inc | Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques |
IL297844A (en) * | 2015-10-02 | 2023-01-01 | Complexa Inc | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
JP2018064553A (ja) * | 2016-10-18 | 2018-04-26 | 株式会社あじかん | 粉末油脂の製造方法、油脂含有食品の製造方法、及び、粉末油脂 |
-
2019
- 2019-02-22 FR FR1901820A patent/FR3092968B1/fr active Active
-
2020
- 2020-02-21 JP JP2021545685A patent/JP2022521048A/ja active Pending
- 2020-02-21 CA CA3142490A patent/CA3142490A1/fr active Pending
- 2020-02-21 CN CN202080016194.8A patent/CN113924001A/zh active Pending
- 2020-02-21 AU AU2020225432A patent/AU2020225432A1/en active Pending
- 2020-02-21 MX MX2021009825A patent/MX2021009825A/es unknown
- 2020-02-21 BR BR112021016556-8A patent/BR112021016556A2/pt unknown
- 2020-02-21 WO PCT/FR2020/050330 patent/WO2020169936A1/fr unknown
- 2020-02-21 KR KR1020217030200A patent/KR20210130190A/ko active Search and Examination
- 2020-02-21 SG SG11202109081SA patent/SG11202109081SA/en unknown
- 2020-02-24 US US16/798,609 patent/US11806316B2/en active Active
-
2021
- 2021-08-06 ZA ZA2021/05588A patent/ZA202105588B/en unknown
- 2021-08-19 IL IL285726A patent/IL285726A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020225432A1 (en) | 2021-08-19 |
CN113924001A (zh) | 2022-01-11 |
FR3092968B1 (fr) | 2021-05-21 |
FR3092968A1 (fr) | 2020-08-28 |
BR112021016556A2 (pt) | 2021-10-26 |
IL285726A (en) | 2021-10-31 |
MX2021009825A (es) | 2021-12-10 |
ZA202105588B (en) | 2023-01-25 |
US11806316B2 (en) | 2023-11-07 |
KR20210130190A (ko) | 2021-10-29 |
WO2020169936A1 (fr) | 2020-08-27 |
SG11202109081SA (en) | 2021-09-29 |
CA3142490A1 (fr) | 2020-08-27 |
US20200268816A1 (en) | 2020-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kijlstra et al. | Lutein: more than just a filter for blue light | |
JP2022521048A (ja) | 食品サプリメント | |
US6140365A (en) | Preparation of microorganisms comprising omega-3-fatty acid for use as a prophylactic or therapeutic agent against parasitic diseases of animals | |
CN105079009B (zh) | 预防和/或治疗心脑血管疾病的组合物 | |
Bowen-Forbes et al. | Fats | |
WO2018176150A1 (en) | Fish egg extracts, omega-3 lipid-based compositions and uses thereof | |
JP2016065097A (ja) | 神経再生剤 | |
Hoffman et al. | Gut microbiome-modulated dietary strategies in EAE and multiple sclerosis | |
WO2011080982A1 (ja) | うつ病又はうつ状態の予防又は治療用油脂組成物 | |
CN108289863B (zh) | 包含三萜类的组合物 | |
EP0391218A2 (en) | Agent for the atopy prophylaxis | |
RU2809772C2 (ru) | Пищевая добавка | |
CN113244206A (zh) | 单不饱和脂肪酸组合物和治疗动脉粥样硬化的应用 | |
US20240016866A1 (en) | Food supplement | |
EP0437334B1 (en) | Method of producing a fatty acid | |
EP3927183A1 (fr) | Complément alimentaire | |
Hadley et al. | Preclinical safety evaluation in rats using a highly purified ethyl ester of algal-docosahexaenoic acid | |
JP4594489B2 (ja) | 特異的殺癌細胞剤及びこれを配合してなる組成物 | |
WO2023063321A1 (ja) | 抗アレルギー剤 | |
WO2024024395A1 (ja) | 視神経障害の予防または治療のための医薬または飲食品組成物 | |
WO2022075375A1 (ja) | トランスサイレチン四量体安定化剤、及び、トランスサイレチンアミロイドーシス予防剤又は進行抑制剤 | |
Islam et al. | Effects of feeding palm oil and soybean oil on body weight and blood cholesterol in black Bengal goats | |
JP2000086425A (ja) | 美白剤およびこれを配合してなる美白用組成物 | |
RU2211043C2 (ru) | Композиция для приготовления лекарственных форм и обогащения продуктов питания, способствующая коррекции нарушений липидного обмена, профилактики и лечения атеросклероза | |
Loucaides | The effects of Omega-3, Omega-6 Polyunsaturated Fatty Acids (PUFAs) and Vitamin E on patients with the remitting-relapsing (RR) form of Multiple Sclerosis (MS) in Cyprus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230120 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230518 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240516 |